Literature DB >> 24861668

Vaccines against human diarrheal pathogens: current status and perspectives.

Nathalie Böhles1, Nathalie Böhles1, Kim Busch1, Kim Busch1, Michael Hensel1, Michael Hensel1.   

Abstract

Worldwide, nearly 1.7 billion people per year contract diarrheal infectious diseases (DID) and almost 760 000 of infections are fatal. DID are a major problem in developing countries where poor sanitation prevails and food and water may become contaminated by fecal shedding. Diarrhea is caused by pathogens such as bacteria, protozoans and viruses. Important diarrheal pathogens are Vibrio cholerae, Shigella spp. and rotavirus, which can be prevented with vaccines for several years. The focus of this review is on currently available vaccines against these three pathogens, and on development of new vaccines. Currently, various types of vaccines based on traditional (killed, live attenuated, toxoid or conjugate vaccines) and reverse vaccinology (DNA/mRNA, vector, recombinant subunit, plant vaccines) are in development or already available. Development of new vaccines demands high levels of knowledge, experience, budget, and time, yet promising new vaccines often fail in preclinical and clinical studies. Efficacy of vaccination also depends on the route of delivery, and mucosal immunization in particular is of special interest for preventing DID. Furthermore, adjuvants, delivery systems and other vaccine components are essential for an adequate immune response. These aspects will be discussed in relation to the improvement of existing and development of new vaccines against DID.

Entities:  

Keywords:  Shigellaspp. Campylobacterspp.; Vibrio cholerae; diarrheal diseases; human pathogen; oral vaccine; recombinant vaccine; rotavirus

Mesh:

Substances:

Year:  2014        PMID: 24861668      PMCID: PMC5396248          DOI: 10.4161/hv.29241

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  116 in total

1.  Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.

Authors:  Edwin V Oaks; K Ross Turbyfill
Journal:  Vaccine       Date:  2005-12-05       Impact factor: 3.641

2.  Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.

Authors:  L F Fries; A D Montemarano; C P Mallett; D N Taylor; T L Hale; G H Lowell
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

Review 3.  2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis.

Authors:  Jacqueline E Tate; Anthony H Burton; Cynthia Boschi-Pinto; A Duncan Steele; Jazmin Duque; Umesh D Parashar
Journal:  Lancet Infect Dis       Date:  2011-10-24       Impact factor: 25.071

4.  Immune response against lipopolysaccharide and invasion plasmid-coded antigens of shigellae in Vietnamese and Swedish dysenteric patients.

Authors:  P D Cam; T Pál; A A Lindberg
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

Review 5.  Cholera toxin - a foe & a friend.

Authors:  Joaquin Sanchez; Jan Holmgren
Journal:  Indian J Med Res       Date:  2011-02       Impact factor: 2.375

6.  Diarrheal disease during Operation Desert Shield.

Authors:  K C Hyams; A L Bourgeois; B R Merrell; P Rozmajzl; J Escamilla; S A Thornton; G M Wasserman; A Burke; P Echeverria; K Y Green
Journal:  N Engl J Med       Date:  1991-11-14       Impact factor: 91.245

7.  Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.

Authors:  Jinming Li; Yanli Sun; Tingting Jia; Rui Zhang; Kuo Zhang; Lunan Wang
Journal:  Int J Cancer       Date:  2013-10-08       Impact factor: 7.396

Review 8.  Accelerating next-generation vaccine development for global disease prevention.

Authors:  Wayne C Koff; Dennis R Burton; Philip R Johnson; Bruce D Walker; Charles R King; Gary J Nabel; Rafi Ahmed; Maharaj K Bhan; Stanley A Plotkin
Journal:  Science       Date:  2013-05-31       Impact factor: 47.728

9.  Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media.

Authors:  Karen L Kotloff; Jakub K Simon; Marcela F Pasetti; Marcelo B Sztein; Stacey L Wooden; Sofie Livio; James P Nataro; William C Blackwelder; Eileen M Barry; Wendy Picking; Myron M Levine
Journal:  Hum Vaccin       Date:  2007-07-15

10.  Thimerosal-Derived Ethylmercury Is a Mitochondrial Toxin in Human Astrocytes: Possible Role of Fenton Chemistry in the Oxidation and Breakage of mtDNA.

Authors:  Martyn A Sharpe; Andrew D Livingston; David S Baskin
Journal:  J Toxicol       Date:  2012-06-28
View more
  5 in total

Review 1.  Recent advances in the production of recombinant subunit vaccines in Pichia pastoris.

Authors:  Man Wang; Shuai Jiang; Yefu Wang
Journal:  Bioengineered       Date:  2016-04       Impact factor: 3.269

Review 2.  Plant-made oral vaccines against human infectious diseases-Are we there yet?

Authors:  Hui-Ting Chan; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2015-09-07       Impact factor: 9.803

Review 3.  Combination vaccines against diarrheal diseases.

Authors:  Malabi M Venkatesan; Lillian L Van de Verg
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Clinical features, risk factors, and impact of antibiotic treatment of diarrhea caused by Shigella in children less than 5 years in Manhiça District, rural Mozambique.

Authors:  Delfino Vubil; Sozinho Acácio; Llorenç Quintò; Clara Ballesté-Delpierre; Tacilta Nhampossa; Karen Kotloff; Myron M Levine; Pedro Alonso; James P Nataro; Tamer H Farag; Jordi Vila; Inacio Mandomando
Journal:  Infect Drug Resist       Date:  2018-10-31       Impact factor: 4.003

5.  Safety and Immunogenicity of a Shigella Bivalent Conjugate Vaccine (ZF0901) in 3-Month- to 5-Year-Old Children in China.

Authors:  Yi Mo; Wenjian Fang; Hong Li; Junji Chen; Xiaohua Hu; Bin Wang; Zhengli Feng; Honghua Shi; Ying He; Dong Huang; Zhaojun Mo; Qiang Ye; Lin Du
Journal:  Vaccines (Basel)       Date:  2021-12-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.